Analysts Offer Insights on Materials Companies: Ball (BALL), Harmony Gold Mining (HMY) and Elanco Animal Health (ELAN)

Analysts fell to the sidelines weighing in on Ball (BALL – Research Report), Harmony Gold Mining (HMY – Research Report) and Elanco Animal Health (ELAN – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Ball (BALL)

Ball received a Hold rating and a $58.00 price target from J.P. Morgan analyst Jeffrey Zekauskas yesterday. The company’s shares closed last Tuesday at $56.62, close to its 52-week low of $54.77.

According to TipRanks.com, Zekauskas is a 5-star analyst with an average return of 6.9% and a 60.1% success rate. Zekauskas covers the Basic Materials sector, focusing on stocks such as Compass Minerals International, Scotts Miracle-Gro Company, and Air Products and Chemicals.

Currently, the analyst consensus on Ball is a Hold with an average price target of $66.13.

See the top stocks recommended by analysts >>

Harmony Gold Mining (HMY)

J.P. Morgan analyst Dominic OKane maintained a Hold rating on Harmony Gold Mining yesterday and set a price target of $3.40. The company’s shares closed last Tuesday at $2.72, close to its 52-week low of $2.69.

According to TipRanks.com, OKane is a 4-star analyst with an average return of 10.0% and a 63.1% success rate. OKane covers the Basic Materials sector, focusing on stocks such as Sibanye Stillwater, Anglogold Ashanti, and Anglo American.

Harmony Gold Mining has an analyst consensus of Hold.

Elanco Animal Health (ELAN)

Elanco Animal Health received a Hold rating and a $24.00 price target from J.P. Morgan analyst Chris Schott yesterday. The company’s shares closed last Tuesday at $15.03, close to its 52-week low of $15.00.

According to TipRanks.com, Schott is a 1-star analyst with an average return of -1.1% and a 48.6% success rate. Schott covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Horizon Therapeutics, and Teva Pharmaceutical.

The word on The Street in general, suggests a Hold analyst consensus rating for Elanco Animal Health with a $21.60 average price target, a 39.7% upside from current levels. In a report issued on August 18, Morgan Stanley also downgraded the stock to Hold with a $22.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BALL:

• Akoya to Participate at Four Upcoming Investor Conferences
• Whistleblower Claims Could Weaken Twitter’s (NYSE:TWTR) Battle Against Musk
• FangDD Reports First Half 2022 Unaudited Financial Results
• Vera Bradley Announces Second Quarter Fiscal Year 2023 Results
• BrewBilt Reports $1M in 2nd QTR Sales With $10M on the Horizon